Trade Names:Pyridoxine Hydrochloride- Tablets 10 mg- Tablets 25 mg- Tablets 50 mg- Tablets 100 mg- Tablets 200 mg- Tablets 250 mg- Tablets, extended-release 200 mg- Capsules 500 mg- Solution 200 mg per 5 mL
Trade Names:Pyri-500- Tablets 500 mg
Trade Names:Rodex- Capsules 150 mg
Trade Names:Vitabee-6- Injection 100 mg/mLHexa-Betalin (Canada)
Vitamin B 6 functions as coenzyme in amino acid, carbohydrate, and lipid metabolism.
Absorbed by passive diffusion in the jejunum and to a lesser extent in the ileum.
Primarily stored in the liver, lesser amount in the muscle and brain. Not protein bound.
Metabolized in the liver and converted to 4-pyridoxic acid metabolite.
Excreted mostly as 4-pyridoxic acid in the urine. The t ½ is 15 to 20 days.
Pyridoxine deficiency, including inadequate diet, drug-induced causes (eg, isoniazid, hydralazine, oral contraceptives) or inborn errors of metabolism. Parenteral use is indicated when oral therapy is not feasible.
Treatment of hydrazine poisoning, PMS, hyperoxaluria type I, nausea and vomiting in pregnancy, sideroblastic anemia associated with high serum iron, carpal tunnel syndrome, tardive dyskinesia.
PO / IM / IV 10 to 20 mg/day for 3 wk.Drug-Induced Deficiency Anemia or NeuritisAdults
PO / IM / IV 100 to 200 mg/day for 3 wk; follow with 25 to 100 mg/day.NeuropathyAdults
PO / IM / IV 50 to 200 mg/day.Vitamin B 6 Dependency SyndromeAdults
PO / IM / IV 600 mg, followed by 30 mg/day for life. Dependency has been noted in adults administered 200 mg/day.Pyridoxine-dependent infants
IM / IV 10 to 100 mg, followed by 2 to 100 mg/day.Metabolic DisordersAdults
PO / IM / IV 100 to 500 mg/day.Isoniazid PoisoningAdults and children
IV 4 g IV followed by 1 g IM every 30 min until pyridoxine dose equal to isoniazid dose has been given.
Store all forms of drug at room temperature in tightly closed, light-resistant containers. Avoid freezing injection.
Increased need for pyridoxine.Levodopa
Decreased effect of levodopa. (Interaction does not occur with levodopa/carbidopa in combination with pyridoxine.)Phenytoin
Phenytoin serum levels may be decreased.
Incompatible with alkaline solutions, iron salts and oxidizing agents (parenteral).
May result in false-positive urobilinogen in the spot test using Ehrlich reagent.
Neuropathy; unstable gait; drowsiness; somnolence.
Numbness of feet; decreased sensation to touch, temperature or vibration; paresthesia; low serum folic acid levels; burning/stinging at IM injection site; photoallergic reaction; ataxia.
Category A . ( Category C in doses that exceed the RDA.)
Excreted in breast milk; may inhibit lactation.
Safety and efficacy not established in doses exceeding nutritional requirements.
Ataxia, sensory neuropathy.
Copyright © 2009 Wolters Kluwer Health.